Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.

Victoria FurerTali EviatarTal FreundHagit PelegDaphna ParanDavid LevartovskyIlana KaufmanAdi BroydeOfir ElaloufAri PolachekJoy FeldAmir HaddadTal GazittMuna EliasNizar HigaziFadi KharoufSmadar GertelSara PelSharon NevoDavid HaginDevy ZismanOri Elkayam

Published in: Annals of the rheumatic diseases (2022)

The two-dose BNTb262 regimen was associated with similar clinical efficacy and similar waning of the humoral response over 6 months among patients with AIIRD and controls. The third vaccine dose restored the humoral response in all of the controls and the majority of patients.

Keyphrases

immune response
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
multiple sclerosis
oxidative stress
patient reported outcomes
binding protein
drug induced